NCT07782164Recruiting
Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
Irreversible Electroporation (IRE) of Recurrent Pelvic Tumors: the PELFIRE Study.
Source: ClinicalTrials.gov · Last updated 28 Aug 2026
Brief summary (registry, in English)
The goal of this single-center observational cohort study, based on a registry combining retrospectively and prospectively collected data, is to investigate the short- and long-term effects of irreversible electroporation (IRE) in men and women over the age of 18 who receive IRE for recurrence of pelvic tumors not suitable for other local treatment options such as surgery, thermal ablation, and radiotherapy. The main question it aims to answer is whether IRE is safe in this population, and secondarily, whether it is effective in controlling local tumor recurrence.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 27 (estimated)
- First submitted
- 8 Aug 2026
- Start date
- 18 Apr 2025
- Primary completion date
- Jun 2028
- Lead sponsor
- Amsterdam UMC, location VUmc
- Diseases
- Prostate cancer, Kidney cancer, Bladder cancer, Cervical cancer, Lung cancer, Colorectal cancer, Ovarian cancer
- NCT number
- NCT07782164
What you commit to
- Study type: Observational
- Planned participants: 27
- From 18 Apr 2025 to the primary completion date, Jun 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- If the treated tumor was biopsied directly prior to MWA and pathology proves the lesion to represent a benign entity;
Other
- Inadequate or insufficient data registered;
- Inadequate or insufficient follow-up;
Who the study is looking for
- Measurable disease described on pre-treatment imaging (CT/MRI/PET-CT) (max 6 weeks prior);
- IRE of a recurrent pelvic tumor;
- Unsuitable for other local therapies (surgery/stereotactic body radiation therapy) as described during the multidisciplinary tumor board;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amsterdam UMC Coordinator of this site? Confirm its status | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.